Nonmedication Devices in Development for the Treatment of Alzheimer's Disease

被引:0
作者
Sleem, Tamara [1 ]
Decourt, Boris [2 ]
Sabbagh, Marwan N. [1 ]
机构
[1] Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurol, Phoenix, AZ USA
[2] Texas Tech Univ Hlth Sci Ctr, Sch Med, Dept Pharmacol & Neurosci, Lubbock, TX USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trials; devices; treatment; DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; COGNITIVE FUNCTION; SYNAPTIC PLASTICITY; CORTEX EXCITABILITY; DOUBLE-BLIND; PHOTOBIOMODULATION; CONNECTIVITY; DEMENTIA;
D O I
10.3233/ADR-230115
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huge investments continue to be made in treatment for Alzheimer's disease (AD), with more than one hundred drugs currently in development. Pharmacological approaches and drug development, particularly those targeting amyloid-beta, have dominated the therapeutic landscape. At the same time, there is also a growing interest in devices for treating AD. This review aimed to identify and describe devices under development for AD treatment. In this review, we queried the devices that are in development for the treatment of AD. PubMed was searched through the end of 2021 using the terms "device," "therapeutics," and "Alzheimer's" for articles that report on devices to treat AD. Ten devices with 31 references were identified as actively being developed for the treatment of AD. Many of these devices are far along in development. Device-based therapies are often overlooked when evaluating treatment approaches to AD. However, many devices for treating AD are in development and some show promising results.
引用
收藏
页码:241 / 255
页数:15
相关论文
共 50 条
  • [41] The "rights" of precision drug development for Alzheimer's disease
    Cummings, Jeffrey
    Feldman, Howard H.
    Scheltens, Philip
    ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)
  • [42] Alzheimer's disease drug development pipeline: 2020
    Cummings, Jeffrey
    Lee, Garam
    Ritter, Aaron
    Sabbagh, Marwan
    Zhong, Kate
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2020, 6 (01)
  • [43] Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease
    Stummer, Lauren
    Markovic, Marija
    Maroney, Megan
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2020, 10 (04) : 205 - 217
  • [44] Viral Hypothesis and Antiviral Treatment in Alzheimer's Disease
    Devanand, D. P.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (09)
  • [45] Treatment and Management of Dementia Due to Alzheimer’s Disease
    Jennifer Rose V. Molano
    Robin Bratt
    Rhonna Shatz
    Current Treatment Options in Neurology, 2015, 17
  • [46] Ginkgolides and Huperzine A for complementary treatment of Alzheimer's disease
    Villegas, Cecilia
    Perez, Rebeca
    Petiz, Lyvia Lintzmaier
    Glaser, Talita
    Ulrich, Henning
    Paz, Cristian
    IUBMB LIFE, 2022, 74 (08) : 763 - 779
  • [47] Treatment and Management of Dementia Due to Alzheimer's Disease
    Molano, Jennifer Rose V.
    Bratt, Robin
    Shatz, Rhonna
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (08)
  • [48] Treatment of Behavioral and Psychological Symptoms of Alzheimer's Disease
    Corbett, Anne
    Smith, Jessica
    Creese, Byron
    Ballard, Clive
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (02) : 113 - 125
  • [49] Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease
    Ning, Shen
    Jorfi, Mehdi
    Patel, Shaun R.
    Kim, Doo Yeon
    Tanzi, Rudolph E.
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [50] Reviewing the Role of Donepezil in the Treatment of Alzheimer's Disease
    Doody, Rachelle S.
    Cummings, Jeffrey L.
    Farlow, Martin R.
    CURRENT ALZHEIMER RESEARCH, 2012, 9 (07) : 773 - 781